Oak Ridge Investments LLC Sells 1,118 Shares of Biohaven Ltd. $BHVN

Oak Ridge Investments LLC lessened its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 5.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,246 shares of the company’s stock after selling 1,118 shares during the period. Oak Ridge Investments LLC’s holdings in Biohaven were worth $272,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. SVB Wealth LLC bought a new stake in shares of Biohaven during the 1st quarter valued at $25,000. PNC Financial Services Group Inc. boosted its holdings in shares of Biohaven by 53.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company’s stock valued at $43,000 after buying an additional 623 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Biohaven by 84,800.0% during the 1st quarter. IFP Advisors Inc now owns 2,547 shares of the company’s stock valued at $61,000 after buying an additional 2,544 shares in the last quarter. KBC Group NV boosted its holdings in shares of Biohaven by 35.0% during the 1st quarter. KBC Group NV now owns 4,560 shares of the company’s stock valued at $110,000 after buying an additional 1,183 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Biohaven by 62.8% during the 1st quarter. US Bancorp DE now owns 4,837 shares of the company’s stock valued at $116,000 after buying an additional 1,866 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

BHVN opened at $15.89 on Monday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.82 and a current ratio of 3.82. The stock has a market capitalization of $1.68 billion, a P/E ratio of -2.07 and a beta of 1.03. The company’s 50-day simple moving average is $14.97 and its two-hundred day simple moving average is $16.29. Biohaven Ltd. has a 52-week low of $12.79 and a 52-week high of $54.98.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, August 11th. The company reported ($1.94) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.94). As a group, analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Bank of America dropped their price target on shares of Biohaven from $50.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Raymond James Financial raised shares of Biohaven from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. cut their price objective on shares of Biohaven from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 18th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective (down from $54.00) on shares of Biohaven in a research report on Tuesday, August 12th. Finally, Leerink Partners cut their price objective on shares of Biohaven from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Biohaven currently has an average rating of “Buy” and a consensus price target of $48.85.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.